Medscape

The Management of High Risk Melanoma: Staging, Treatment and Nursing Issues

The AJCC staging is based on three main characteristics defining the natural history of melanoma; namely the extent of the primary tumor (T), the absence or presence of regional lymph node metastasis ...
Nasdaq

Castle Biosciences Presents Innovative Research on Melanoma Risk Stratification at ASCO 2025

Castle Biosciences, Inc. will present innovative research on cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 ASCO Annual Meeting in Chicago, showcasing findings from a collaboration with ...
Healio

Melanoma tumors thicker than 0.8 mm increase risk for death

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The crude incidence rate of melanoma-related death 20 ...
Nasdaq

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

Patients identified as low risk by DecisionDx-Melanoma had a 2.8% sentinel lymph node (SLN) positivity rate, well below the National Comprehensive Cancer Network® (NCCN) guidelines’ 5% threshold to ...
Seeking Alpha

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to ...